Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INH vs PASKALIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.
PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.
First-line treatment and prophylaxis of tuberculosis (TB) caused by Mycobacterium tuberculosis
Treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with other antituberculosis agents
300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.
PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.
Fast acetylators: 0.5-1.5 hours; slow acetylators: 2-4 hours. Clinically, slow acetylators have higher risk of peripheral neuropathy and hepatotoxicity.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via N-acetyltransferase 2 (NAT2); also metabolized by cytochrome P450 (CYP2E1) to hepatotoxic metabolites.
PASKALIUM is hydrolyzed in the gastrointestinal tract to PAS; PAS is primarily metabolized via acetylation (N-acetyltransferase) and conjugation with glycine.
Renal: 75-95% as unchanged drug and metabolites (including acetylisoniazid, isonicotinic acid). Biliary/fecal: minor (<5%).
Primarily renal (70-80% as unchanged drug); biliary/fecal (15-20%); metabolized in liver (5-10%).
0-10% (low binding; primarily albumin).
98% bound, primarily to alpha-1-acid glycoprotein (AAG) and albumin.
0.6-0.8 L/kg (distributes into total body water, including cerebrospinal fluid and tuberculous cavities).
Vd: 0.8-1.2 L/kg; suggests extensive tissue distribution, likely due to high lipophilicity.
Oral: ~90%. Intramuscular: ~100%.
Oral: 85-90% (first-pass metabolism minimal); intramuscular: 95%; intravenous: 100%.
In patients with GFR < 30 m L/min, reduce dose to 200 mg daily or 300 mg three times weekly. For GFR 30-50 m L/min, no adjustment necessary. For GFR < 10 m L/min, consider 150 mg daily or 300 mg twice weekly.
GFR >60: no adjustment; GFR 30-60: 250 mg daily; GFR <30: 125 mg daily.
In Child-Pugh class A, no adjustment. In Child-Pugh class B, reduce dose to 200 mg daily. In Child-Pugh class C, use 150 mg daily or avoid if severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: 125 mg daily.
10-15 mg/kg orally once daily (max 300 mg) for active tuberculosis; for latent tuberculosis, 10-15 mg/kg orally once daily (max 300 mg) or 20-40 mg/kg orally twice weekly (max 900 mg per dose).
10 mg/kg/day orally in divided doses every 12 hours.
No specific dose adjustment required, but monitor for hepatotoxicity and peripheral neuropathy, especially in patients with comorbidities or polypharmacy.
Start at 250 mg daily; adjust based on renal function.
Severe and sometimes fatal hepatitis (especially in patients >35 years, daily alcohol users, and those with pre-existing liver disease); monitor hepatic function closely.
None.
Hepatotoxicity (monitor LFTs, discontinue if signs of hepatitis),Peripheral neuropathy (pyridoxine prophylaxis recommended),CNS effects (seizures, psychosis; avoid in active CNS disease),Lupus-like syndrome,Drug interactions (e.g., carbamazepine, phenytoin)
May cause gastrointestinal irritation, hepatotoxicity, and hypersensitivity reactions. Monitor liver function and renal function during therapy.
Acute liver disease,History of INH-induced hepatotoxicity,Previous severe adverse reaction (e.g., drug fever, arthritis)
Hypersensitivity to para-aminosalicylic acid or any component of the formulation,Severe renal impairment (Cr Cl < 30 m L/min)
Foods high in tyramine (e.g., aged cheese, cured meats, soy products) may rarely cause hypertensive crisis in patients also taking MAOIs, though interaction is less significant with INH alone. High-fat meals may delay absorption, so avoid fatty foods near dosing time. No specific dietary restrictions beyond taking on empty stomach.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, tomatoes). Use of potassium-containing salt substitutes is contraindicated.
INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential for hepatotoxicity and peripheral neuropathy, and possibly increased risk of neonatal hemorrhage due to vitamin K deficiency.
PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcomes. First trimester: no known risk. Second trimester: no known risk. Third trimester: maternal electrolyte disturbances may affect fetal heart rate and uterine contractility.
INH is excreted into breast milk in low concentrations (M/P ratio approximately 1.6). Breastfeeding is generally considered safe, but monitor infant for signs of peripheral neuropathy or liver toxicity. The American Academy of Pediatrics considers INH compatible with breastfeeding.
Potassium is a normal constituent of breast milk. PASKALIUM is compatible with breastfeeding. M/P ratio: not applicable as potassium is endogenous. No adverse effects on nursing infant reported.
No dose adjustment is routinely required for pregnancy. However, due to increased clearance (30-50% higher), some experts recommend monitoring serum INH levels and adjusting dose to maintain therapeutic levels. Pyridoxine supplementation (25-50 mg/day) is recommended to prevent peripheral neuropathy.
Pregnancy may alter potassium distribution due to increased plasma volume. Dosing should be individualized based on serum potassium levels. No fixed dose adjustment required; titrate to maintain normal potassium levels (3.5-5.0 m Eq/L).
Administer on an empty stomach (1 hour before or 2 hours after meals) to maximize absorption. Monitor liver function tests (ALT, AST) at baseline and monthly during therapy. Pyridoxine (vitamin B6) 25-50 mg/day should be co-administered to prevent peripheral neuropathy. Hepatotoxicity risk increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Slow acetylators are more prone to toxicity. Patients with liver disease require careful monitoring and dose adjustment.
PASKALIUM is a potassium-sparing diuretic used for hypertension and edema. Monitor serum potassium regularly; avoid in severe renal impairment or hyperkalemia. Coadministration with ACE inhibitors or NSAIDs increases hyperkalemia risk.
Take on an empty stomach with a full glass of water.,Do not drink alcohol while taking this medication due to increased risk of liver damage.,Report immediately any signs of liver problems: dark urine, yellowing of skin or eyes, persistent nausea, or abdominal pain.,Take vitamin B6 as prescribed to prevent numbness or tingling in hands and feet.,Complete full course of therapy even if you feel better to prevent resistance.,Avoid antacids within 1 hour of taking this medication as they may reduce absorption.
Take exactly as prescribed; do not skip doses or double up.,Avoid potassium-rich foods and salt substitutes unless directed.,Report muscle weakness, irregular heartbeat, or signs of hyperkalemia.,May cause dizziness; avoid driving until effects known.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INH vs PASKALIUM, answered by our medical review team.
INH is a Antitubercular Agent that works by INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.. PASKALIUM is a Antitubercular Agent that works by PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INH and PASKALIUM depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INH is: 300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.. The standard adult dose of PASKALIUM is: PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INH and PASKALIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INH is classified as Category C. INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential. PASKALIUM is classified as Category C. PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcom. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.